Sana Biotechnology develops engineered cell therapies for type 1 diabetes and B cell diseases, based in Seattle. SANA reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 14 | B of A Securities | Maintained | Buy |
Seasonality
How SANA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in SANA in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SANA is in one of them and how their past SANA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SANA in an article yet. Here's the latest on the wider market.
About Sana Biotechnology
Sana Biotechnology is a biotechnology company based in Seattle, Washington, that develops engineered cell therapies. Its lead candidate, SC451, is meant to treat type 1 diabetes with cells that can be transplanted without immunosuppression. Its in vivo CAR T candidate, SG293, is being developed for B cell cancers and B cell mediated autoimmune diseases. The company's products are still in development and are aimed at patients with these conditions.
- Headquarters
- Seattle, WA
- Website
- sana.com ↗